Parkinson disease 10

Summary

Parkinson disease 10 (MONDO:0011737) is a disease and 4 clinical trials. A subtype of young-onset Parkinson disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	Parkinson disease 10
Mondo ID	MONDO:0011737
MeSH	C564653
OMIM	606852
UMLS	C1847360
MedGen	339741
GARD	0018607
Is cancer (heuristic)	no

Also known as: PARK10 · Parkinson disease 10

Disease family

This is a subtype of young-onset Parkinson disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › brain disorder › basal ganglia disorder › parkinsonian disorder › Parkinson disease › young-onset Parkinson disease › Parkinson disease 10

Related subtypes (8): juvenile-onset Parkinson disease, Parkinson disease 12, autosomal recessive juvenile Parkinson disease 2, Parkinson disease 3, autosomal dominant, autosomal recessive early-onset Parkinson disease 6, autosomal recessive early-onset Parkinson disease 7, early-onset Parkinson disease 20, autosomal recessive early-onset Parkinson disease 23

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	4

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01835652	Not specified	COMPLETED	The Effects of Exercise in Parkinson’s Disease
NCT03355521	Not specified	COMPLETED	Effects of Nordic Walking in Parkinson Disease Patients
NCT03860649	Not specified	UNKNOWN	Effects of Different Physical Therapies and Dance in People With Parkinson’s Disease
NCT04422353	Not specified	UNKNOWN	Video Dance Class and Unsupervised Physical Activity During Covid-19 Pandemic in People With Parkinson’s Disease